Show simple item record

dc.contributor.authorKumar, Nathella Pavan
dc.contributor.authorMoideen, Kadar
dc.contributor.authorNancy, Arul
dc.contributor.authorViswanathan, Vijay
dc.contributor.authorShruthi, Basavaradhya S.
dc.contributor.authorSivakumar, Shanmugam
dc.contributor.authorHissar, Syed
dc.contributor.authorKornfeld, Hardy
dc.contributor.authorBabu, Subash
dc.date2022-08-11T08:09:55.000
dc.date.accessioned2022-08-23T16:48:34Z
dc.date.available2022-08-23T16:48:34Z
dc.date.issued2019-12-09
dc.date.submitted2020-01-02
dc.identifier.citation<p>BMC Infect Dis. 2019 Dec 9;19(1):1039. doi: 10.1186/s12879-019-4648-1. <a href="https://doi.org/10.1186/s12879-019-4648-1">Link to article on publisher's site</a></p>
dc.identifier.issn1471-2334 (Linking)
dc.identifier.doi10.1186/s12879-019-4648-1
dc.identifier.pmid31818258
dc.identifier.urihttp://hdl.handle.net/20.500.14038/41298
dc.description.abstractBACKGROUND: Ligands of the receptor for advanced glycation end products (RAGE) are key signalling molecules in the innate immune system but their role in tuberculosis-diabetes comorbidity (TB-DM) has not been investigated. METHODS: We examined the systemic levels of soluble RAGE (sRAGE), advanced glycation end products (AGE), S100A12 and high mobility group box 1 (HMGB1) in participants with either TB-DM, TB, DM or healthy controls (HC). RESULTS: Systemic levels of AGE, sRAGE and S100A12 were significantly elevated in TB-DM and DM in comparison to TB and HC. During follow up, AGE, sRAGE and S100A12 remained significantly elevated in TB-DM compared to TB at 2nd month and 6th month of anti-TB treatment (ATT). RAGE ligands were increased in TB-DM individuals with bilateral and cavitary disease. sRAGE and S100A12 correlated with glycated hemoglobin levels. Within the TB-DM group, those with known diabetes (KDM) revealed significantly increased levels of AGE and sRAGE compared to newly diagnosed DM (NDM). KDM participants on metformin treatment exhibited significantly diminished levels of AGE and sRAGE in comparison to those on non-metformin regimens. CONCLUSIONS: Our data demonstrate that RAGE ligand levels reflect disease severity and extent in TB-DM, distinguish KDM from NDM and are modulated by metformin therapy.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=31818258&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rights© The Author(s). 2019 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectDiabetes mellitus
dc.subjectMycobacterium tuberculosis
dc.subjectRAGE ligands
dc.subjectBacterial Infections and Mycoses
dc.subjectEndocrine System Diseases
dc.subjectHemic and Immune Systems
dc.subjectImmunology and Infectious Disease
dc.subjectInfectious Disease
dc.subjectNutritional and Metabolic Diseases
dc.titleSystemic RAGE ligands are upregulated in tuberculosis individuals with diabetes co-morbidity and modulated by anti-tuberculosis treatment and metformin therapy
dc.typeJournal Article
dc.source.journaltitleBMC infectious diseases
dc.source.volume19
dc.source.issue1
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=5103&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/4084
dc.identifier.contextkey16101186
refterms.dateFOA2022-08-23T16:48:34Z
html.description.abstract<p>BACKGROUND: Ligands of the receptor for advanced glycation end products (RAGE) are key signalling molecules in the innate immune system but their role in tuberculosis-diabetes comorbidity (TB-DM) has not been investigated.</p> <p>METHODS: We examined the systemic levels of soluble RAGE (sRAGE), advanced glycation end products (AGE), S100A12 and high mobility group box 1 (HMGB1) in participants with either TB-DM, TB, DM or healthy controls (HC).</p> <p>RESULTS: Systemic levels of AGE, sRAGE and S100A12 were significantly elevated in TB-DM and DM in comparison to TB and HC. During follow up, AGE, sRAGE and S100A12 remained significantly elevated in TB-DM compared to TB at 2nd month and 6th month of anti-TB treatment (ATT). RAGE ligands were increased in TB-DM individuals with bilateral and cavitary disease. sRAGE and S100A12 correlated with glycated hemoglobin levels. Within the TB-DM group, those with known diabetes (KDM) revealed significantly increased levels of AGE and sRAGE compared to newly diagnosed DM (NDM). KDM participants on metformin treatment exhibited significantly diminished levels of AGE and sRAGE in comparison to those on non-metformin regimens.</p> <p>CONCLUSIONS: Our data demonstrate that RAGE ligand levels reflect disease severity and extent in TB-DM, distinguish KDM from NDM and are modulated by metformin therapy.</p>
dc.identifier.submissionpathoapubs/4084
dc.contributor.departmentDepartment of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine
dc.source.pages1039


Files in this item

Thumbnail
Name:
document.pdf
Size:
1016.Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© The Author(s). 2019 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Except where otherwise noted, this item's license is described as © The Author(s). 2019 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.